|
|
| Author |
Message |
derdrittemann2003@yahoo.c medicine forum Guru
Joined: 11 Sep 2005
Posts: 1799
|
Posted: Wed May 24, 2006 4:19 pm Post subject:
Are LymeNUTs or mice? ( More hilarity from LymeNUT)
|
|
|
More Lyme-looniness over at LymeNUT...apparently some don't read too
carefully and have kneejerked a reaction to a vaccine for MICE.
Yes, that's right...a vaccine for mice. An interesting idea...which
would break the chain of infection, reduce incidence, by orally
vaccinating mice through baited stations.
But the LymeNUTS see the words "vaccine" and "new" and go
all-giddy/hysterical. One recommends that no one take this "vaccine".
(See: "New Lyme Vaccine: Anyone trust this")? (Medical Questions).
And then..."MCSWEEGAN" gets added to the mix. Looks like they have
confused his March 16 letter to the editor of Nature (the one that
Brucie gets quoted in) as applying to this situation...in a different
thread...(And I believe Sweeg was talking about efforts to produce a
new human vaccine, referred to in the third paragraph below)...
And NOW...oh hell...who cares? It's a twisted comedy...of sorts.
Here's the real story on the mouse vaccine:
Vaccine Production
NIAID-funded investigators have developed an experimental bait delivery
system for an OspA-based vaccine against B. burgdorferi in which mice
are immunized orally (via gavage or bait feeding) with a strain of
Escherichia coli expressing the gene for OspA. This results in the
appearance of serum antibody specific for OspA. Upon exposure to Ixodes
nymphs carrying multiple strains of B. burgdorferi, oral vaccination
was found to protect 89% of the mice from infection and the resultant
serum antibody response confirmed the presence of IgG2a/2b antibody
specific for OspA. This vaccination approach is able to generate a
significant protective immune response against a variety of infectious
strains of B. burgdorferi, thereby indicating that it can eliminate B.
burgdorferi from a major host reservoir. It suggests that the broad
delivery of an oral vaccine to wildlife reservoirs in an endemic area
is likely to disrupt the transmission of Lyme disease (Vaccine, in
press). These findings are consistent with the results reported by
other investigators (Proc Natl Acad Sci 52: 18159, 2004), thereby
affirming the utility of this approach.
In other studies, NIAID grantees have developed a murine-targeted OspA
vaccine utilizing Vaccinia virus to interrupt the transmission of
disease in reservoir hosts, thereby having the potential to reduce the
incidence of human disease. Oral vaccination of mice with a single dose
of Vaccinia expressing OspA resulted in high antibody titers to OspA,
100 percent protection of vaccinated mice from infection by B.
burgdorferi, and a significant clearance of B. burgdorferi from
infected ticks fed on vaccinated animals (Vaccine 24: 1949, 2006).
These findings indicate that such a vaccine may effectively reduce the
incidence of Lyme disease in endemic areas. Field studies of this
vaccine are planned.
NIAID also is funding preclinical studies on developing and testing
other candidate vaccines (for example, decorin-binding protein A or
DbpA) for Lyme disease. MedImmune, Inc. (an NIAID Small Business
Innovation Research grantee) and Sanofi-Aventis Pharmaceuticals,
reported that a combination vaccine composed of the DbpA and OspA of B.
burgdorferi is more effective than either given alone in preventing the
development of borreliosis in experimental animals. On the basis of
these encouraging findings, both companies have entered into an
agreement to develop a new, more effective second-generation vaccine to
prevent Lyme disease in humans. Although the results of previous
studies indicate that DbpA induces the development of protective
immunity in a murine model of Lyme borreliosis when mice are challenged
(needle inoculated) intradermally with in vitro-cultivated B.
burgdorferi, such mice are not protected from infection transmitted by
ticks carrying virulent B. burgdorferi.
Home | Help | Site Index | Accessibility | Privacy Policy | Disclaimer
| Web Site Links & Policies | FOIA | Last Updated September 8, 2005
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH) Department of Health and Human
Services (HHS) |
|
| Back to top |
|
 |
Nutcracker medicine forum Guru
Joined: 02 Mar 2006
Posts: 318
|
Posted: Wed May 24, 2006 5:00 pm Post subject:
Re: Are LymeNUTs or mice? ( More hilarity from LymeNUT)
|
|
|
Yukon King wrote:
| Quote: | But the LymeNUTS see the words "vaccine" and "new" and go
all-giddy/hysterical. One recommends that no one take this "vaccine".
|
LOL.
Hilarious. |
|
| Back to top |
|
 |
Chuck P Adams medicine forum Guru
Joined: 03 Aug 2005
Posts: 1335
|
Posted: Wed May 24, 2006 5:43 pm Post subject:
Re: Are LymeNUTs or mice? ( More hilarity from LymeNUT)
|
|
|
This is a classic example why it's a waste of time to release a vaccine
with internet nuts claiming the thing is a failure before it hits the
market.
I guess a vaccine puts a squeeze on the fund raising dollars and cash
only witch doctors and bogus labs. Keep the fear of God in them and
they will blindly keep pumping that money into the bank account.
Right Pat! |
|
| Back to top |
|
 |
derdrittemann2003@yahoo.c medicine forum Guru
Joined: 11 Sep 2005
Posts: 1799
|
Posted: Wed May 24, 2006 5:49 pm Post subject:
Re: Are we LymeNUTs or mice? ( More hilarity from LymeNUT)
|
|
|
Elected Newsgroup leader Chuck wrote:
| Quote: | This is a classic example why it's a waste of time to release a vaccine
with internet nuts claiming the thing is a failure before it hits the
market.
I guess a vaccine puts a squeeze on the fund raising dollars and cash
only witch doctors and bogus labs. Keep the fear of God in them and
they will blindly keep pumping that money into the bank account.
Right Pat!
|
Looks like I accidentally removed the original post.
Here is the stuff they are really talking about...
Vaccine Production
NIAID Research: Vaccine Production
NIAID-funded investigators have developed an experimental bait delivery
system for an OspA-based vaccine against B. burgdorferi in which mice
are immunized orally (via gavage or bait feeding) with a strain of
Escherichia coli expressing the gene for OspA. This results in the
appearance of serum antibody specific for OspA. Upon exposure to Ixodes
nymphs carrying multiple strains of B. burgdorferi, oral vaccination
was found to protect 89% of the mice from infection and the resultant
serum antibody response confirmed the presence of IgG2a/2b antibody
specific for OspA. This vaccination approach is able to generate a
significant protective immune response against a variety of infectious
strains of B. burgdorferi, thereby indicating that it can eliminate B.
burgdorferi from a major host reservoir. It suggests that the broad
delivery of an oral vaccine to wildlife reservoirs in an endemic area
is likely to disrupt the transmission of Lyme disease (Vaccine, in
press). These findings are consistent with the results reported by
other investigators (Proc Natl Acad Sci 52: 18159, 2004), thereby
affirming the utility of this approach.
In other studies, NIAID grantees have developed a murine-targeted OspA
vaccine utilizing Vaccinia virus to interrupt the transmission of
disease in reservoir hosts, thereby having the potential to reduce the
incidence of human disease. Oral vaccination of mice with a single dose
of Vaccinia expressing OspA resulted in high antibody titers to OspA,
100 percent protection of vaccinated mice from infection by B.
burgdorferi, and a significant clearance of B. burgdorferi from
infected ticks fed on vaccinated animals (Vaccine 24: 1949, 2006).
These findings indicate that such a vaccine may effectively reduce the
incidence of Lyme disease in endemic areas. Field studies of this
vaccine are planned.
NIAID also is funding preclinical studies on developing and testing
other candidate vaccines (for example, decorin-binding protein A or
DbpA) for Lyme disease. MedImmune, Inc. (an NIAID Small Business
Innovation Research grantee) and Sanofi-Aventis Pharmaceuticals,
reported that a combination vaccine composed of the DbpA and OspA of B.
burgdorferi is more effective than either given alone in preventing the
development of borreliosis in experimental animals. On the basis of
these encouraging findings, both companies have entered into an
agreement to develop a new, more effective second-generation vaccine to
prevent Lyme disease in humans. Although the results of previous
studies indicate that DbpA induces the development of protective
immunity in a murine model of Lyme borreliosis when mice are challenged
(needle inoculated) intradermally with in vitro-cultivated B.
burgdorferi, such mice are not protected from infection transmitted by
ticks carrying virulent B. burgdorferi. |
|
| Back to top |
|
 |
eugeneshapiroisapig medicine forum Guru
Joined: 24 Mar 2005
Posts: 2108
|
Posted: Thu May 25, 2006 6:36 pm Post subject:
Re: Are we LymeNUTs or mice? ( More hilarity from LymeNUT)
|
|
|
this is good news, I would far prefer wildlife vaccines which preclude
greedy vicious lying insurance whore pigs like gary wormser who have
zero empathy and understanding of late stage neuropsychiatric disease
manifestations and no tolerance for admitting the virtually criminal
acts they have committed in drawing a fraudulent serologic standard
from reaping profits off human clinical trials in order to finance
their depraved and utterly parasitic lives.
unfortunately, experience with wildlife vaccines thus far in the wild
indicates that there are severe obstacles which exist, among them the
presence of multiple species, both mammalian and avian, which serve as
nymphal hosts - as well as the fact that in the wild, most mice are
already infected, and only young mice which have not been exposed will
benefit from the vaccine. The previous study by fish showed I believe a
25% reduction in human disease incidence, which is not enough to
justify the employment of this strategy on a wide scale. In any event
it will be several years before vaccines, wildlife or human, are
employed to control the disease. |
|
| Back to top |
|
 |
derdrittemann2003@yahoo.c medicine forum Guru
Joined: 11 Sep 2005
Posts: 1799
|
Posted: Thu May 25, 2006 10:58 pm Post subject:
Re: Are we LymeNUTs or mice? ( More hilarity from LymeNUT)
|
|
|
Chuck P Adams wrote:
| Quote: | this is good news, I would far prefer wildlife vaccines...
|
Thanks for letting us know.
I will be able to sleep tonight now, not worrying about how you feel
about mouse vaccines. |
|
| Back to top |
|
 |
Nutcracker medicine forum Guru
Joined: 02 Mar 2006
Posts: 318
|
Posted: Thu May 25, 2006 11:10 pm Post subject:
Re: Are we LymeNUTs or mice? ( More hilarity from LymeNUT)
|
|
|
Yukon King wrote:
| Quote: | Chuck P Adams wrote:
this is good news, I would far prefer wildlife vaccines...
Thanks for letting us know.
I will be able to sleep tonight now, not worrying about how you feel
about mouse vaccines.
|
Same here, I have sleepless nights when I don't know Spottdrossel's
opinion about something. *rolling eyes* |
|
| Back to top |
|
 |
eugeneshapiroisapig medicine forum Guru
Joined: 24 Mar 2005
Posts: 2108
|
Posted: Fri May 26, 2006 4:45 pm Post subject:
Re: Are we LymeNUTs or mice? ( More hilarity from LymeNUT)
|
|
|
that's funny, I have sleepless nights because I DO know your opinions
about things. |
|
| Back to top |
|
 |
Google
|
|
| Back to top |
|
 |
|
|
The time now is Wed Jan 07, 2009 6:28 pm | All times are GMT
|
|
Record Internet Radio with Tags | Web Advertising | Bankruptcy | Debt Consolidation | Advertising
|
|
Copyright © 2004-2005 DeniX Solutions SRL
|
|
Other DeniX Solutions sites:
electronics forum,
Science forum
Unix/Linux blog
Unix/Linux documentation
Unix/Linux forums
|
Powered by phpBB © 2001, 2005 phpBB Group
|
|